Compare JYD & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYD | MBIO |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.6M |
| IPO Year | 2022 | 2023 |
| Metric | JYD | MBIO |
|---|---|---|
| Price | $0.77 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 346.9K | 63.5K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.53 |
| 52 Week High | $6.85 | $7.00 |
| Indicator | JYD | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.70 | 42.95 |
| Support Level | $0.54 | $0.58 |
| Resistance Level | $1.07 | $0.82 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 16.09 | 8.97 |
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, fragmented logistics, and chartered airline freight services, supply chain management, and other value-added services.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.